Apis Capital Advisors’s Solid Biosciences SLDB Stock Holding History

Apis Capital Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Hold	160,000	–	–	0.16%	52
2026 Q1	$1.15M	Sell	160,000 -36,000	-18%	-$231K	0.18%	38
2025 Q4	$1.11M	Hold	196,000	–	–	0.19%	40
2025 Q3	$1.21M	Sell	196,000 -4,000	-2%	-$23.4K	0.27%	39
2025 Q2	$974K	Buy	200,000 +90,000	+82%	+$318K	0.35%	33
2025 Q1	$407K	Buy	+110,000	New	+$471K	0.2%	41

Other funds holding SLDB

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Apis Capital Advisors's SLDB Position: Q2 2026 in Review

Apis Capital Advisors held its Solid Biosciences (SLDB) position steady in Q2 2026 at 160,000 shares worth $1.6M. The position accounts for 0.16% of the portfolio, ranked #52.

Apis Capital Advisors first reported a position in SLDB in Q1 2025 and has held it in 6 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Apis Capital Advisors held 160,000 shares of Solid Biosciences worth $1.6M as of Q2 2026.
Apis Capital Advisors left its Solid Biosciences share count unchanged in Q2 2026.
Solid Biosciences made up 0.16% of Apis Capital Advisors's portfolio in Q2 2026, its #52 holding.
Apis Capital Advisors first reported a position in Solid Biosciences in Q1 2025 and has held it in 6 quarters since.
156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Apis Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.